ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,208.00
      0.23%
      Dow Jones
      39,118.86
      0.00%
      Brent Oil
      85.445
      0.39%
      Bitcoin
      62,678.57
      0.13%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NGM Biopharmaceuticals Inc (NGM)

      7. NGM Biopharmaceuticals Inc (NGM) News

      NGM

      NGM Biopharmaceuticals (NGM)

      NGM Biopharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NGM
      DateTimeSourceHeadlineSymbolCompany
      12/20/20224:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NGMNGM Biopharmaceuticals Inc
      12/14/20224:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      12/14/20224:28PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      12/14/20224:24PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      12/12/20227:00PMGlobeNewswire Inc.NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      12/09/202210:10AMTipRanksAnalysts Are Bullish on These Healthcare Stocks: NGM Biopharmaceuticals (NGM), Alcon (ALC)NASDAQ:NGMNGM Biopharmaceuticals Inc
      12/07/20226:45PMGlobeNewswire Inc.NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/23/20224:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/23/20224:18PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/23/20224:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/07/20224:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/07/20224:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/07/20228:00AMGlobeNewswire Inc.NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/04/20228:00AMGlobeNewswire Inc.NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/03/20224:24PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/03/20224:05PMGlobeNewswire Inc.NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/03/20221:00PMGlobeNewswire Inc.NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      10/31/20225:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      10/27/20226:58PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      10/27/20226:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      10/19/20226:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
      10/17/20224:35PMTipRanksNGM Biopharmaceuticals (NGM) was downgraded to a Hold Rating at Piper SandlerNASDAQ:NGMNGM Biopharmaceuticals Inc
      10/17/202210:38AMTipRanksNGM Bio Tanks after NGM621 Fails in Phase 2 StudyNASDAQ:NGMNGM Biopharmaceuticals Inc
      10/17/20227:41AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NGMNGM Biopharmaceuticals Inc
      10/17/20227:30AMGlobeNewswire Inc.NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationNASDAQ:NGMNGM Biopharmaceuticals Inc
      10/16/20224:30PMGlobeNewswire Inc.NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationNASDAQ:NGMNGM Biopharmaceuticals Inc
      09/13/20225:30PMGlobeNewswire Inc.NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic CancerNASDAQ:NGMNGM Biopharmaceuticals Inc
      09/06/20228:00AMGlobeNewswire Inc.NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual CongressNASDAQ:NGMNGM Biopharmaceuticals Inc
      08/15/20228:00AMGlobeNewswire Inc.NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial ofNASDAQ:NGMNGM Biopharmaceuticals Inc
      08/04/20224:34PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NGMNGM Biopharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:NGM

      Your Recent History

      BIT
      UB3CW2
      Unicredit Bank
      Delayed Upgrade Clock